Galectin-3 expression favors metastasis in murine melanoma


Galectin-3 is a member of the lectin family that binds β-galactosides and plays an important role in several types of tumors. Melanoma is an invasive cancer responsible for 80% of deaths associated to skin cancers. There are some evidences that galectin-3 interacts with β-catenin, a molecule involved with Wnt signaling pathway. Here, we evaluate the role of galectin-3 intumor growth and metastasis, as well as its interaction with β-catenin. Murine melanoma cells (B16F10) were injected subcutaneously and intravenously in male C57BL/6 wild-type (WT) and galectin-3 knock-out (KO) mice. Tumor growth and lung melanoma colonies were assessed. The expression of galectin-3 and β-catenin was evaluated by immuno-histochemistry. We observed that tumor growth did not differ between the groups. However, to metastasis, the number of lung colonies in WT mice was significantly increased in comparison to that observed in KO mice. The cytoplasm expression of galectin-3 was observed in subcutaneous and metastatic tumors,w in both groups. We observed its nuclear expression in some of subcutaneous tumors of KO mice. The expression of β-catenin was detected in cell membrane of all subcutaneous tumors analyzed, whereas in the metastatic tumors we observed both cytoplasm and cell membrane staining. Altogether, our data suggest that galectin-3 favors the metastasis of melanoma cells and this process is not associated with β-catenin.

Share and Cite:

Comodo, A. , Lacerda Bachi, A. , Soares, M. , Franco, M. and Castro Teixeira, V. (2013) Galectin-3 expression favors metastasis in murine melanoma. Advances in Bioscience and Biotechnology, 4, 55-62. doi: 10.4236/abb.2013.410A3007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Tucker, M.A. and Goldstein, A.M. (2003) Melanoma etiology: Where are we? Oncogene, 22, 3042-3052.
[2] Chambers, A.F., Groom, A.C. and MacDonald, I.C. (2002) Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2, 563-572.
[3] Gaggioli, C. and Sahai, E. (2007) Melanoma invasion— Current knowledge and future directions. Pigment Cell Research, 20, 161-172.
[4] Clark, W.H., Elder, D.E., Guerry, D., Epstein, M.N., Greene, M.H. and Van Horn, M. (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathology, 15, 1147-1165.
[5] Song, Y.K., Billiar, T.R. and Lee, Y.J. (2002) Role of galectin-3 in breast cancer metastasis: Involvement of nitric oxide. American Journal of Pathology, 160, 1069-1075.
[6] Prieto, V.G., Mourad-Zeidan, A.A., Melnikova, V., Johnson, M.M., Lopez, A., Diwan, A.H., et al. (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clinical Cancer Research, 12, 6709-6715.
[7] Takenaka, Y., Inohara, H., Yoshii, T., Oshima, K., Nakahara, S., Akahani, S., et al. (2003) Malignant transformation of thyroid follicular cells by galectin-3. Cancer Letters, 195, 111-119.
[8] Tsuboi, K., Shimura, T., Masuda, N., Ide, M., Tsutsumi, S., Yamaguchi, S., et al. (2007) Galectin-3 expression in colorectal cancer: Relation to invasion and metastasis. Anticancer Research, 27, 2289-2296.
[9] Barondes, S.H., Castronovo, V., Cooper, D.N., Cummings, R.D., Drickamer, K., Feizi, T., et al. (1994) Galectins: A family of animal beta-galactoside-binding lectins. Cell, 76, 597-598.
[10] Barondes, S.H., Cooper, D.N., Gitt, M.A. and Leffler, H.G. (1994) Structure and function of a large family of animal lectins. The Journal of Biological Chemistry, 269, 20807-20810.
[11] Dumic, J., Dabelic, S. and Flogel, M. (2006) Galectin-3: An open-ended story. Biochim Biophys Acta, 1760, 616-635.
[12] Liu, F.T. and Rabinovich, G.A. (2005) Galectins as modulators of tumour progression. Nature Reviews Cancer, 5, 29-41.
[13] Shimura, T., Takenaka, Y., Fukumori, T., Tsutsumi, S., Okada, K., Hogan, V., et al. (2005) Implication of galectin-3 in Wnt signaling. Cancer Research, 65, 3535-3537.
[14] Shimura, T., Takenaka, Y., Tsutsumi, S., Hogan, V., Kikuchi, A. and Raz, A. (2004) Galectin-3, a novel binding partner of beta-catenin. Cancer Research, 64, 6363-6367.
[15] Weinberger, P.M., Adam, B.L., Gourin, C.G., Moretz, W.H., Bollag, R.J., Wang, B.Y., et al. (2007) Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Archives of Otolaryngology—Head and Neck Surgery, 133, 503-510.
[16] Klingensmith, J. and Nusse, R. (1994) Signaling by wingless in Drosophila. Developmental Biology, 166, 396-414.
[17] Zhurinsky, J., Shtutman, M. and Ben-Ze’ev, A. (2000) Plakoglobin and beta-catenin: Protein interactions, regulation and biological roles. Journal of Cell Science, 113, 3127-3139.
[18] Zimmerman, Z.F., Kulikauskas, R.M., Bomsztyk, K., Moon, R.T. and Chien, A.J. (2013) Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One, 8, e69593.
[19] Huang, H. and He, X. (2008) Wnt/beta-catenin signaling: New (and old) players and new insights. Current Opinion in Cell Biology, 20, 119-125.
[20] Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S. and Kikuchi, A. (1998) Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO Journal, 17, 1371-1384.
[21] Takenaka, Y., Fukumori, T., Yoshii, T., Oka, N., Inohara, H., Kim, H.R., et al. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Molecular and Cellular Biology, 24, 4395-4406.
[22] Correa, M., Machado, J., Carneiro, C.R., Pesquero, J.B., Bader, M., Travassos, L.R., et al. (2005) Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. International Journal of Cancer, 114, 356-363.
[23] Hsu, D.K., Yang, R.Y., Pan, Z., Yu, L., Salomon, D.R., Fung-Leung, W.P., et al. (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. American Journal of Pathology, 156, 1073-1083.
[24] Tomayko, M.M. and Reynolds, C.P. (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacology, 24, 148-154.
[25] Seidal, T., Balaton, A.J. and Battifora, H. (2001) Interpretation and quantification of immunostains. The American Journal of Surgical Pathology, 25, 1204-1207.
[26] Wick, M.R. and Mills, S.E. (2001) Consensual interpretive guidelines for diagnostic immunohistochemistry. The American Journal of Surgical Pathology, 25, 1208-1210.
[27] Bonitsis, N., Batistatou, A., Karantima, S. and Charalabopoulos, K. (2006) The role of cadherin/catenin complex in malignant melanoma. Experimental Oncology, 28, 187-193.
[28] Kim, H., Lee, J., Hyun, J.W., Park, J.W., Joo, H.G. and Shin, T. (2007) Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biology International, 31, 655-662.
[29] Krishnan, V., Bane, S.M., Kawle, P.D., Naresh, K.N. and Kalraiya, R.D. (2005) Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clinical & Experimental Metastasis, 22, 11-24.
[30] Vereecken, P., Debray, C., Petein, M., Awada, A., Lalmand, M.C., Laporte, M., et al. (2005) Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Archives of Dermatological Research, 296, 353-358.
[31] Harhaji, L., Mijatovic, S., Maksimovic-Ivanic, D., Stojanovic, I., Momcilovic, M., Maksimovic, V., et al. (2008) Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: In vitro and in vivo study. Food and Chemical Toxicology, 46, 1825-1833.
[32] Wong, R.P., Ng, P., Dedhar, S. and Li, G. (2007) The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Molecular Cancer Therapeutics, 6, 1692-1700.
[33] Dietrich, A., Stockmar, C., Aust, G., Endesfelder, S., Guetz, A., Sack, U., et al. (2006) Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. Journal of Cancer Research and Clinical Oncology, 132, 379-388.
[34] Mansour, M., Pohajdak, B., Kast, W.M., Fuentes-Ortega, A., Korets-Smith, E., Weir, G.M., et al. (2007) Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. Journal of Translational Medicine, 5, 20.
[35] Coussens, L.M. and Werb, Z. (2002) Inflammation and cancer. Nature, 420, 860-867.
[36] Califice, S., Castronovo, V., Bracke, M. and van den Brule, F. (2004) Dual activities of galectin-3 in human prostate cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene, 23, 7527-7536.
[37] Honjo, Y., Inohara, H., Akahani, S., Yoshii, T., Takenaka, Y., Yoshida, J., et al. (2000) Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clinical Cancer Research, 6, 4635-4640.
[38] Bachmann, I.M., Straume, O., Puntervoll, H.E., Kalvenes, M.B. and Akslen, L.A. (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research, 11, 8606-8614.
[39] Maelandsmo, G.M., Holm, R., Nesland, J.M., Fodstad, Ø. and FlØrenes, V.A. (2003) Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clinical Cancer Research, 9, 3383-3388.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.